Plasma Rich in Growth Factors in Macular Hole Surgery

Sánchez-Ávila, Ronald Mauricio; Robayo-Esper, Carlos A.; Villota-Deleu, E.; Sanz, Álvaro Fernández-Vega; González, Alvaro Fernández-Vega; Anitua, Eduardo; Merayo‐Lloves, Jesús

doi:10.3390/clinpract12010007

Cited by 9 publications

(1 citation statement)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Plasma rich in growth factors (PRGF) is a blood derivative product of autologous origin with important biological features such as antimicrobial, anti-inflammatory and anti-fibrotic properties. PRGF, in its different therapeutic formulations (eye drops, clot and membrane), has been effectively used to treat several ocular surface and corneal diseases [6,7] and even in macular-hole surgery [8,9], demonstrating its role in tissular regeneration, inflammation control and fibrosis modulation [10,11]. The biological properties of PRGF would theoretically be of great help in reducing fibrosis after NPDS.…”

Section: Introductionmentioning

confidence: 99%

Plasma Rich in Growth Factors as an Adjuvant Agent in Non-Penetrating Deep Sclerectomy

Rodríguez-Calvo

Rodríguez-Uña

Fernández-Vega-Cueto

et al. 2023

JCM

Self Cite

View full text Add to dashboard Cite

Background: The purpose of this study is to evaluate the utility and safety of plasma rich in growth factors immunosafe eye drops (is-ePRGF) in the postoperative treatment of non-penetrating deep sclerectomy (NPDS). Methods: This is a case–control study in patients with open-angle glaucoma. Group one (control) was not treated with is-ePRGF, while group two (is-ePRGF) was treated (four times a day for four months). Postoperative evaluations were performed at one day, one month, three months and six months. The main outcomes were: intraocular pressure (IOP), microcysts in blebs with AS-OCT and the number of hypotensive eye drops. Results: Preoperatively, group one (n = 48 eyes) and group two (n = 47 eyes) were similar in age (71.5 ± 10.7 vs. 70.9 ± 10.0 years; p = 0.68), IOP (20.6 ± 10.2 vs. 23.0 ± 9.0 mmHg; p = 0.26) and number of hypotensive drugs (2.7 ± 0.8 vs. 2.8 ± 0.9; p = 0.40). The IOP at six months dropped to 15.0 ± 8.0 mmHg (IOP reduction: −27.2%) and 10.9 ± 4.3 mmHg (IOP reduction: −52.6%) for group one and group two, respectively (p < 0.01). At six months, blebs with microcysts were 62.5% (group one) and 76.7% (group two). Postoperative complications were observed in 12 eyes (25%) for group one and in 5 eyes (11%) for group two (p = 0.06). No specific complications related to the use of is-ePRGF were identified. Conclusions: Topical is-ePRGF seems to reduce IOP and the rate of complications in the medium term after NPDS, so it can be considered as a possible safe adjuvant to achieve surgical success.

show abstract

Section: Introductionmentioning

confidence: 99%

Plasma Rich in Growth Factors as an Adjuvant Agent in Non-Penetrating Deep Sclerectomy

Rodríguez-Calvo

Rodríguez-Uña

Fernández-Vega-Cueto

et al. 2023

JCM

Self Cite

View full text Add to dashboard Cite

show abstract

Platelet concentrates in macular hole surgery. A journey through the labyrinth of terminology, preparation, and application: a comprehensive review

Gelormini,

D’antico,

Ricardi

et al. 2024

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

The surgical management of macular holes is undergoing continuous evolution, with recent focus on the utilization of platelet concentrates as a promising adjunctive intervention. Currently, they present a valid surgical approach for achieving anatomical and functional success with a non-inferiority comparably to the alternative surgical techniques. Nonetheless, the utilization of varied platelet concentrates terminologies, coupled with the lack of standardization in their preparation methodologies, engenders both lexical confusion and challenges in comparing scientific studies published up until now. In this review, we summarized the published evidence concerning the application of platelet concentrates in macular holes surgery, aiming to clarify the terminology and methodologies employed and to establish a common consensus facilitating further development and diffusion of this promising technique.

show abstract

Unilateral Macular Hole in a Patient With Retinitis Pigmentosa Treated With Cover Flap Technique With the Use of Platelet-Rich Plasma Under Air Tamponade

Lo Giudice,

Alessandria,

Imburgia

et al. 2024

RETINAL Cases &Amp; Brief Reports

View full text Add to dashboard Cite

Purpose: The purpose of the study is to show the excellent anatomical result of the inverted flap-assisted technique with PRP under air for retinitis pigmentosa complicated with macular hole Methods: A 32-year-old woman, previously diagnosed with retinitis pigmentosa, was referred to our department complaining of decreased central vision in her LEFT eye for 4 weeks. At the time of presentation, the optical coherence tomography and fundoscopy examination showed the presence of a macular hole of 620 microns in diameter. The closure of the macular hole was observed after the surgical procedure, but endophthalmitis occurred 5 days postoperatively. Results: In our presented case, the cover flap-assisted technique with PRP under air for retinitis pigmentosa complicated with macular hole resulted in excellent anatomical outcomes with unremarkable visual recovery. Conclusion: The physiopathology of full-thickness macular holes in RP patients remains still not fully elucidated. Pars plana vitrectomy with the adjunct of highly concentrated P-PRP have shown successful results.

show abstract

Plasma Rich in Growth Factors in Macular Hole Surgery

Cited by 9 publications

References 51 publications

Plasma Rich in Growth Factors as an Adjuvant Agent in Non-Penetrating Deep Sclerectomy

Plasma Rich in Growth Factors as an Adjuvant Agent in Non-Penetrating Deep Sclerectomy

Platelet concentrates in macular hole surgery. A journey through the labyrinth of terminology, preparation, and application: a comprehensive review

Unilateral Macular Hole in a Patient With Retinitis Pigmentosa Treated With Cover Flap Technique With the Use of Platelet-Rich Plasma Under Air Tamponade

Contact Info

Product

Resources

About